Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Global Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia program that includes intravenous interferon beta-1a as a new treatment arm has been approved.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable